Effects of valsartan and spironolactone on insulin-like growth factor-1 in cardiacmyocytes of spontaneously hypertensive rats

duan xiao chun,wang jin ming,wang fang,li heng,qin jin mei
DOI: https://doi.org/10.3969/j.issn.1009-2501.2004.10.013
2004-01-01
Abstract:AIM: To study the inhibitive effects of valsartan and spironolactone on expression of insulin like growth factor 1 in cardiacmyocytes of spontaneously hypertensive rats. METHODS: 18 SHRs were randomly divided into 3 groups (n=6 in each): valsartan group treated with 30 mg·kg -1 ·d -1 valsartan, spironolactone group treated with 20 mg·kg -1 ·d -1 spironolactone, and control group treated with placebo. All were administrated by gastric perfusion. 6 WKY rats were served as control. After 13 weeks administration, the expressions of IGF 1 in cardiacmycytes were measured by immunohistochemistry and the IGF 1 concentrations in myocardium were measured by radiommunoassay. RESULTS: The expression of IGF 1 was higher in SHR group than that in the WKY group (P 0.01 ). Valsartan and spironolactone inhibited the expression of IGF 1. The inhibitive effects of IGF 1 in valsartan group were more significantly higher than those in spironolactone group. Valsartan and spironolactone decreased blood pressure and left ventricular mass to body weight ratio (LVM/BW). CONCLUSION: IGF 1 may play an important role in the development of cardiac hypertrophy in SHR. Valsartan and spironolactone treatment can inhibit the expression of IGF 1 and prophylaxi myocardial hypertrophy.
What problem does this paper attempt to address?